Luca Malatesta

Dr. Luca Malatesta

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
VRValentina Raglianti
Valentina Raglianti
MAMaria Lucia Angelotti
Maria Lucia Angelotti
LCLuigi Cirillo
Luigi Cirillo
FBFrancesca Becherucci
Francesca Becherucci
LCLetizia De Chiara
Letizia De Chiara
PRPaola Romagnani
Paola Romagnani
Key Points: Anti–slit autoantibody profiles identified different podocytopathy phenotypes, with anti-podocin/KIRREL1 associated with FSGS and steroid resistance. Anti-nephrin, anti-podocin, and anti-KIRREL1 testing improved risk stratification, identifying patients at a risk of CKD and post-transplant recurrence. Background: Anti-nephrin, anti-podocin, and anti-KIRREL1 antibodies are increasingly recognized as causes of autoimmune podocytopathies, yet autoantibody-specific clinical phenotypes remain poorly defined. Methods: We conducted a multicenter study integrating serology and super-resolution microscopy in 471 samples, including 213 cases with 146 kidney biopsies (minimal change n =63, FSGS n =83), and sera from 128 patients (minimal changes n =30, FSGS n =42, idiopathic nephrotic syndrome or isolated proteinuria n =56), including 61 paired specimens plus 258 controls (75 kidney biopsies, 200 sera, including 17 paired specimens). Paired specimens were used to assess ELISA performance by comparing serum results with IgG colocalization of target proteins within the filtration slit using receiver operating characteristic curves. All assays showed high specificity but lower sensitivity than super-resolution microscopy. Clinical features and long-term outcomes associated with individual autoantibodies and their combinations were also evaluated. Results: Anti–slit diaphragm antibodies were detected in 67/213 patients: 63% had anti-nephrin, 9% anti-podocin, or 3% anti-KIRREL1 antibodies only, while 25% had multiple autoantibodies. Isolated anti-nephrin antibodies were associated with minimal changes (91%), steroid sensitivity (88%), and absence of CKD over 120 months. In contrast, anti-podocin and/or anti-KIRREL1 antibodies correlated with FSGS (84%), steroid resistance (58%), CKD progression (36%), and kidney failure (24%). Among 26 transplant recipients with FSGS, early post-transplant recurrence occurred in 83% of autoantibodies carriers and in 5% of the others. Recurrent patients showed anti-podocin/KIRREL1 antibodies, with or without anti-nephrin. Conclusions: These findings suggest that anti-podocin and anti-KIRREL1 antibodies associate with steroid resistance, FSGS, and disease recurrence after transplantation in autoimmune podocytopathies.

3 July 2026 in Antibodies
Verified
Journal Article
Open access
PDF file
MAMarco Allinovi
Marco Allinovi
LMLuca Malatesta
Luca Malatesta
TBTiziana Biagioli
Tiziana Biagioli
EAElisabetta Antonioli
Elisabetta Antonioli
FPfederico perfetto
federico perfetto
Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding resistance mechanisms. Drawing on experience from other better-studied monoclonal antibodies, resistance to daratumumab can be categorized into four main mechanisms: (1) reduced CD38 expression on plasma cells; (2) increased expression of complement inhibitory proteins (CD55/CD59), impairing complement-mediated cytotoxicity; (3) reduced drug bioavailability due to urinary loss in non-selective nephrotic syndrome; and (4) the development of neutralizing anti-daratumumab antibodies. Anti-drug antibodies (ADAs) may represent a potential mechanism of treatment failure through effects on pharmacokinetics, efficacy, and safety, even in patients on daratumumab therapy. Seven different trials have tested anti-daratumumab antibodies. Among them, anti-daratumumab antibodies were identified in only 0–2.4% of patients, and only in a small portion of these has it been proven to be neutralizing. Overall, ADAs appear rare, but these findings are likely underestimated due to short follow-up and suboptimal timing of assessment. In conclusion, standardized ADA monitoring, particularly months after treatment interruption or in cases of inadequate response or infusion-related reactions, may improve patient management and therapeutic outcomes.

30 September 2026 in Kidney International Case Reports
Verified
Journal Article
Open access
LMLuca Malatesta
Luca Malatesta
CRCarlotta Rella
Carlotta Rella
SDSara D’AMico
Sara D’AMico
FAFederica Allegretta
Federica Allegretta
ALAida Larti
Aida Larti
IGIacopo Gianassi
Iacopo Gianassi

26 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LMLuca Malatesta
Luca Malatesta
MAMarco Allinovi
Marco Allinovi
SBSofia Brucia
Sofia Brucia
MCMariapia Carafa
Mariapia Carafa
SLSara Dal Lago
Sara Dal Lago
FPFrancesco Peyronel
Francesco Peyronel
Background: The urea-to-creatinine ratio (UCR) is used to support the differential diagnosis of acute kidney injury (AKI); however, its diagnostic utility remains debated. We explored the clinical relevance of UCR in the initial etiological assessment of AKI, also considering relevant clinical modifiers. Methods: We retrospectively analyzed 590 hospitalized patients classified as pre-renal (n = 319), parenchymal (n = 135), or post-renal (n = 136) AKI. UCR was compared across AKI subtypes and stratified by pre-existing chronic kidney disease (CKD). Logistic regression models assessed the association between UCR and pre-renal AKI, excluding post-renal cases. Diagnostic performance was evaluated using receiver operating characteristic curve analysis. An exploratory analysis was performed within parenchymal AKI according to histopathological patterns and the presence of nephrotic syndrome. Results: Baseline characteristics differed across AKI subtypes, including age, sex, and CKD. UCR was higher in pre-renal than in parenchymal and post-renal AKI (p < 0.001), despite substantial overlap. Stratification by CKD did not reveal differences within AKI subtypes; however, in pre-renal AKI, UCR decreased progressively with advancing CKD stage (p < 0.001). UCR was significantly associated with pre-renal AKI, and diagnostic performance improved when combined with age and advanced CKD. Within parenchymal AKI, higher UCR values were observed in glomerular disease, particularly with nephrotic syndrome. Conclusions: UCR varies across AKI etiologies and is influenced by age and baseline kidney function. Although its standalone diagnostic performance is limited, integration with simple clinical variables improves discrimination between pre-renal and parenchymal AKI, supporting its use as a complementary tool in early AKI evaluation while emphasizing the need for comprehensive clinical assessment.